Dogwood Therapeutics, Inc.: ARMISTICE CAPITAL, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Armistice Capital, LLC filed an amended Schedule 13G with the SEC (accession 0001172661-26-005222) updating its beneficial ownership stake in Dogwood Therapeutics, Inc. The amendment signals a change in the investment firm's position in the clinical-stage biotech, though the filing summary did not disclose the revised share count or percentage. Such 13G amendments are typically triggered when passive investors cross the 5% ownership threshold or when their holdings shift by more than 5% of the class. The update matters because it reveals how a institutional backer is sizing its exposure to Dogwood, whose pipeline and cash position are closely watched by biotech investors. Next, watch for the full filing details to confirm whether Armistice increased, trimmed or maintained its stake, and monitor any subsequent 13D or Form 4 activity for signs of activist intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Armistice Capital, LLC, Dogwood Therapeutics, Inc.